Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06747936
PHASE3
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
Sponsor: Addpharma Inc.
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Official title: A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia.
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2025-02
Completion Date
2026-12
Last Updated
2025-02-04
Healthy Volunteers
No
Conditions
Interventions
DRUG
AD-2281
PO, Once daily, 8weeks
DRUG
AD-2282
PO, Once daily, 8weeks
DRUG
Placebo of AD-2282
PO, Once daily, 8weeks